Becoming Aitia: why GNS shifted from AI provider to drug discoverer
With John Maraganore chairing its board, the causal AI company thinks patient data has matured enough to tap more value from its technology
Aitia’s decision to move into drug discovery after more than 20 years as a technology partner is a bet on its causal AI’s capacity to extract value from the recent boom in multi-omic patient data. The Massachusetts-based company formerly known as GNS Healthcare Inc. is keeping its focus on preclinical development, with plans to partner programs before IND.
CEO Colin Hill told BioCentury the company considered the shift five years ago, seeing appetite from investors and pharma partners, but held off to focus on its core technology, Gemini — an AI platform that uses molecular and clinical patient data to identify the biological circuitry most likely to be causal drivers of disease, and model disease progression and drug response at the individual patient level...